Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma
Highlights • Pancreatic ductal adenocarcinoma (PDAC) is hypovascular. • Vascular endothelial growth factor A (gene: VEGFA) (VEGF-A) is overexpressed in PDAC. • Increased VEGF-A or microvessel density is associated with poor patient outcome. • Blocking VEGF-A in mouse models reduces tumor volumes and...
Gespeichert in:
| Veröffentlicht in: | Cancer letters 2016-10, Vol.381 (1), p.201-210 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 210 |
|---|---|
| container_issue | 1 |
| container_start_page | 201 |
| container_title | Cancer letters |
| container_volume | 381 |
| creator | Craven, Kelly E Gore, Jesse Korc, Murray |
| description | Highlights • Pancreatic ductal adenocarcinoma (PDAC) is hypovascular. • Vascular endothelial growth factor A (gene: VEGFA) (VEGF-A) is overexpressed in PDAC. • Increased VEGF-A or microvessel density is associated with poor patient outcome. • Blocking VEGF-A in mouse models reduces tumor volumes and improves survival. • Clinical trials targeting angiogenesis elicit marginal survival benefit. |
| doi_str_mv | 10.1016/j.canlet.2015.11.047 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4919237</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0304383515007429</els_id><sourcerecordid>4179079781</sourcerecordid><originalsourceid>FETCH-LOGICAL-c645t-37af33c2995e5f390476f5fcebfdee0bfdbb434625457e25b00d115f8c429a733</originalsourceid><addsrcrecordid>eNqNUk1v1DAUtBCILoV_gFAkLlyS-jNOLkioooBUqQfas-U4L6mXrL3Yzlb993XYdkt7gYst682b55l5CL0nuCKY1Cfrymg3QaooJqIipMJcvkAr0khayrbBL9EKM8xL1jBxhN7EuMYYCy7Fa3REa0lZI_kKXV_sIOws3BR-KLYBSjNZZ42eCu364vCIae4txCLpMEKybszl0foRHEQbC-uKrXYmgE7WFP1s0kLQg_NGB2Od3-i36NWgpwjv7u9jdHX29fL0e3l-8e3H6Zfz0tRcpJJJPTBmaNsKEANrs6h6EIOBbugBcD67jjNeU8GFBCo6jHtCxNAYTlstGTtGn_e827nbQG_ApaAntQ12o8Ot8tqqpxVnr9Xod4q3pKVMZoJP9wTB_54hJrWx0cA0aQd-joo0VDYt4Zz9B5Q0jNW14Bn68Rl07efgshN_UKJmLaMZxfcoE3yMAYbDvwlWS-pqrfapqyV1RYjKBuW2D39rPjQ9xPxoCmTnc9pBRWPBGehtAJNU7-2_JjwneFiNX3AL8VGLilRh9XPZvGXxiMBY5mTYHR6E1pM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1818563932</pqid></control><display><type>article</type><title>Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Craven, Kelly E ; Gore, Jesse ; Korc, Murray</creator><creatorcontrib>Craven, Kelly E ; Gore, Jesse ; Korc, Murray</creatorcontrib><description>Highlights • Pancreatic ductal adenocarcinoma (PDAC) is hypovascular. • Vascular endothelial growth factor A (gene: VEGFA) (VEGF-A) is overexpressed in PDAC. • Increased VEGF-A or microvessel density is associated with poor patient outcome. • Blocking VEGF-A in mouse models reduces tumor volumes and improves survival. • Clinical trials targeting angiogenesis elicit marginal survival benefit.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2015.11.047</identifier><identifier>PMID: 26723874</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Angiogenesis ; Angiogenesis Inhibitors - adverse effects ; Angiogenesis Inhibitors - therapeutic use ; Angiogenic Proteins - antagonists & inhibitors ; Angiogenic Proteins - metabolism ; Animals ; Carcinoma, Pancreatic Ductal - blood supply ; Carcinoma, Pancreatic Ductal - drug therapy ; Carcinoma, Pancreatic Ductal - metabolism ; Carcinoma, Pancreatic Ductal - pathology ; Cell division ; Chemotherapy ; Clinical trials ; Confidence intervals ; Drug Resistance, Neoplasm ; Endothelium ; Hematology, Oncology and Palliative Medicine ; Humans ; Kinases ; Metastasis ; Molecular Targeted Therapy ; Neovascularization, Pathologic ; Pancreas ; Pancreatic cancer ; Pancreatic Neoplasms - blood supply ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - metabolism ; Pancreatic Neoplasms - pathology ; Physiology ; Proteins ; Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors ; Receptors, Vascular Endothelial Growth Factor - metabolism ; Response rates ; Rodents ; Signal Transduction - drug effects ; Tumor Microenvironment ; Tumorigenesis ; Tumors ; Vascular endothelial growth factor ; Vascular endothelial growth factor (VEGF) ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Vascular Endothelial Growth Factor A - metabolism</subject><ispartof>Cancer letters, 2016-10, Vol.381 (1), p.201-210</ispartof><rights>The Authors</rights><rights>2015 The Authors</rights><rights>Copyright © 2015 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.</rights><rights>Copyright Elsevier Limited Oct 10, 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c645t-37af33c2995e5f390476f5fcebfdee0bfdbb434625457e25b00d115f8c429a733</citedby><cites>FETCH-LOGICAL-c645t-37af33c2995e5f390476f5fcebfdee0bfdbb434625457e25b00d115f8c429a733</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0304383515007429$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26723874$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Craven, Kelly E</creatorcontrib><creatorcontrib>Gore, Jesse</creatorcontrib><creatorcontrib>Korc, Murray</creatorcontrib><title>Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>Highlights • Pancreatic ductal adenocarcinoma (PDAC) is hypovascular. • Vascular endothelial growth factor A (gene: VEGFA) (VEGF-A) is overexpressed in PDAC. • Increased VEGF-A or microvessel density is associated with poor patient outcome. • Blocking VEGF-A in mouse models reduces tumor volumes and improves survival. • Clinical trials targeting angiogenesis elicit marginal survival benefit.</description><subject>Angiogenesis</subject><subject>Angiogenesis Inhibitors - adverse effects</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Angiogenic Proteins - antagonists & inhibitors</subject><subject>Angiogenic Proteins - metabolism</subject><subject>Animals</subject><subject>Carcinoma, Pancreatic Ductal - blood supply</subject><subject>Carcinoma, Pancreatic Ductal - drug therapy</subject><subject>Carcinoma, Pancreatic Ductal - metabolism</subject><subject>Carcinoma, Pancreatic Ductal - pathology</subject><subject>Cell division</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Confidence intervals</subject><subject>Drug Resistance, Neoplasm</subject><subject>Endothelium</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Kinases</subject><subject>Metastasis</subject><subject>Molecular Targeted Therapy</subject><subject>Neovascularization, Pathologic</subject><subject>Pancreas</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms - blood supply</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - metabolism</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Physiology</subject><subject>Proteins</subject><subject>Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors</subject><subject>Receptors, Vascular Endothelial Growth Factor - metabolism</subject><subject>Response rates</subject><subject>Rodents</subject><subject>Signal Transduction - drug effects</subject><subject>Tumor Microenvironment</subject><subject>Tumorigenesis</subject><subject>Tumors</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular endothelial growth factor (VEGF)</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Vascular Endothelial Growth Factor A - metabolism</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUk1v1DAUtBCILoV_gFAkLlyS-jNOLkioooBUqQfas-U4L6mXrL3Yzlb993XYdkt7gYst682b55l5CL0nuCKY1Cfrymg3QaooJqIipMJcvkAr0khayrbBL9EKM8xL1jBxhN7EuMYYCy7Fa3REa0lZI_kKXV_sIOws3BR-KLYBSjNZZ42eCu364vCIae4txCLpMEKybszl0foRHEQbC-uKrXYmgE7WFP1s0kLQg_NGB2Od3-i36NWgpwjv7u9jdHX29fL0e3l-8e3H6Zfz0tRcpJJJPTBmaNsKEANrs6h6EIOBbugBcD67jjNeU8GFBCo6jHtCxNAYTlstGTtGn_e827nbQG_ApaAntQ12o8Ot8tqqpxVnr9Xod4q3pKVMZoJP9wTB_54hJrWx0cA0aQd-joo0VDYt4Zz9B5Q0jNW14Bn68Rl07efgshN_UKJmLaMZxfcoE3yMAYbDvwlWS-pqrfapqyV1RYjKBuW2D39rPjQ9xPxoCmTnc9pBRWPBGehtAJNU7-2_JjwneFiNX3AL8VGLilRh9XPZvGXxiMBY5mTYHR6E1pM</recordid><startdate>20161010</startdate><enddate>20161010</enddate><creator>Craven, Kelly E</creator><creator>Gore, Jesse</creator><creator>Korc, Murray</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20161010</creationdate><title>Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma</title><author>Craven, Kelly E ; Gore, Jesse ; Korc, Murray</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c645t-37af33c2995e5f390476f5fcebfdee0bfdbb434625457e25b00d115f8c429a733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Angiogenesis</topic><topic>Angiogenesis Inhibitors - adverse effects</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Angiogenic Proteins - antagonists & inhibitors</topic><topic>Angiogenic Proteins - metabolism</topic><topic>Animals</topic><topic>Carcinoma, Pancreatic Ductal - blood supply</topic><topic>Carcinoma, Pancreatic Ductal - drug therapy</topic><topic>Carcinoma, Pancreatic Ductal - metabolism</topic><topic>Carcinoma, Pancreatic Ductal - pathology</topic><topic>Cell division</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Confidence intervals</topic><topic>Drug Resistance, Neoplasm</topic><topic>Endothelium</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Kinases</topic><topic>Metastasis</topic><topic>Molecular Targeted Therapy</topic><topic>Neovascularization, Pathologic</topic><topic>Pancreas</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms - blood supply</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - metabolism</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Physiology</topic><topic>Proteins</topic><topic>Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors</topic><topic>Receptors, Vascular Endothelial Growth Factor - metabolism</topic><topic>Response rates</topic><topic>Rodents</topic><topic>Signal Transduction - drug effects</topic><topic>Tumor Microenvironment</topic><topic>Tumorigenesis</topic><topic>Tumors</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular endothelial growth factor (VEGF)</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Vascular Endothelial Growth Factor A - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Craven, Kelly E</creatorcontrib><creatorcontrib>Gore, Jesse</creatorcontrib><creatorcontrib>Korc, Murray</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Craven, Kelly E</au><au>Gore, Jesse</au><au>Korc, Murray</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2016-10-10</date><risdate>2016</risdate><volume>381</volume><issue>1</issue><spage>201</spage><epage>210</epage><pages>201-210</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>Highlights • Pancreatic ductal adenocarcinoma (PDAC) is hypovascular. • Vascular endothelial growth factor A (gene: VEGFA) (VEGF-A) is overexpressed in PDAC. • Increased VEGF-A or microvessel density is associated with poor patient outcome. • Blocking VEGF-A in mouse models reduces tumor volumes and improves survival. • Clinical trials targeting angiogenesis elicit marginal survival benefit.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>26723874</pmid><doi>10.1016/j.canlet.2015.11.047</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3835 |
| ispartof | Cancer letters, 2016-10, Vol.381 (1), p.201-210 |
| issn | 0304-3835 1872-7980 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4919237 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Angiogenesis Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - therapeutic use Angiogenic Proteins - antagonists & inhibitors Angiogenic Proteins - metabolism Animals Carcinoma, Pancreatic Ductal - blood supply Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - metabolism Carcinoma, Pancreatic Ductal - pathology Cell division Chemotherapy Clinical trials Confidence intervals Drug Resistance, Neoplasm Endothelium Hematology, Oncology and Palliative Medicine Humans Kinases Metastasis Molecular Targeted Therapy Neovascularization, Pathologic Pancreas Pancreatic cancer Pancreatic Neoplasms - blood supply Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - pathology Physiology Proteins Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors Receptors, Vascular Endothelial Growth Factor - metabolism Response rates Rodents Signal Transduction - drug effects Tumor Microenvironment Tumorigenesis Tumors Vascular endothelial growth factor Vascular endothelial growth factor (VEGF) Vascular Endothelial Growth Factor A - antagonists & inhibitors Vascular Endothelial Growth Factor A - metabolism |
| title | Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T17%3A08%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overview%20of%20pre-clinical%20and%20clinical%20studies%20targeting%20angiogenesis%20in%20pancreatic%20ductal%20adenocarcinoma&rft.jtitle=Cancer%20letters&rft.au=Craven,%20Kelly%20E&rft.date=2016-10-10&rft.volume=381&rft.issue=1&rft.spage=201&rft.epage=210&rft.pages=201-210&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2015.11.047&rft_dat=%3Cproquest_pubme%3E4179079781%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1818563932&rft_id=info:pmid/26723874&rft_els_id=1_s2_0_S0304383515007429&rfr_iscdi=true |